Advertisement

Advertisement

antimicrobial stewardship

New Antibiotics Provide a Glimmer of Hope as Older Drugs Grapple With Resistance

Teaser: 

1Nsisong Asanga, MBBCh, MPH, FIMC,

is a physician, field epidemiologist, and freelance health writer whose work has been published by BioSpace, Yahoo, AARP, WebMD, VeryWell, Healthline, Parents, SELF, Health, Insider, The Independent, and other platforms.

CLINICAL TOOLS

Abstract: Antimicrobial resistance (AMR) poses an escalating global threat, with superbugs such as MRSA, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Neisseria gonorrhoeae challenging modern clinical practice. Antibiotic development has stalled due to economic disincentives, regulatory barriers, and scientific complexity. Emerging strategies—including soil-derived compounds such as teixobactin, AI-assisted drug discovery (halicin, abaucin), phage therapy, and novel membrane-disrupting agents—offer cautious optimism. Stewardship, genomic surveillance, and diagnostics remain essential complements to new therapies.
Key Words: antimicrobial resistance (AMR), antibiotic discovery, AI-driven drug design, antimicrobial stewardship.
AMR is an accelerating crisis: The WHO projects AMR could cause up to 10 million deaths annually by 2050, surpassing cancer mortality. Superbugs including MRSA, carbapenem-resistant Enterobacteriaceae, and ceftriaxone-resistant gonorrhea are already threatening routine clinical procedures.
The antibiotic pipeline has been dangerously thin: No novel antibiotic class was discovered and approved between 1987 and 2020. Economic disincentives—including low ROI, short market life (2–3 years before resistance emerges), and costly Phase 3 trial requirements—deter pharmaceutical investment.
Novel discovery platforms are showing promise: Soil-derived teixobactin (Phase 1 safety confirmed in 2024), AI-designed halicin (effective against 35/36 resistant organisms in vitro), and phage therapy agents represent mechanistically distinct pipelines that could outpace traditional resistance evolution.
Stewardship and diagnostics are non-negotiable complements: New antibiotics alone cannot solve AMR. Robust stewardship programs, rapid diagnostics, microbiome-aware prescribing, and global genomic surveillance are required to preserve the efficacy of both current and emerging agents.
The empirical prescribing dilemma is real but manageable: Clinicians face pressure between starting empirical antibiotics (which drives resistance) and waiting for culture results (which delays care). Integrating rapid diagnostics and leveraging AI-assisted resistance pattern analysis can narrow this window, enabling more targeted, timely therapy without reflexively broadening antibiotic coverage.
Stewardship is not the enemy of care: Reserving new agents as ‘last resort’ therapies is clinically rational, but must not translate into access delays for patients with resistant infections. Hospitals should embed stewardship pharmacists and infectious disease consultants in high-risk pathways (oncology, surgery, ICU) to optimize drug selection, dosing, and duration — ensuring that when novel antibiotics arrive, prescribers are already equipped to deploy them appropriately.
To have access to full article that these tools were developed for, please subscribe. The cost to subscribe is $80 USD per year and you will gain full access to all the premium content on www.healthplexus.net, an educational portal, that hosts 1000s of clinical reviews, case studies, educational visual aids and more as well as within the mobile app.
Related Terms: Infectious Diseases, antimicrobial resistance, antibiotic discovery, AI-driven drug design, antimicrobial stewardship
Disclaimer: 
Disclaimer at the end of each page